Physician profile
Eric W Herman
NPI 1073605291
$8,529.31
in general payments reported to CMS, 2019-2025
33 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,304 · 2020: $704 · 2021: $982 · 2022: $1,694 · 2023: $1,578 · 2024: $831 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,766 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,766.04 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,041.50 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $674.82 | 2022-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $646.29 | 2019-2025 | |
| Journey Medical Corporation | $643.32 | 2019-2023 | |
| Lilly USA, LLC | $596.63 | 2021-2025 | Taltz, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $574.97 | 2019-2025 | Cabtreo |
| Regeneron Healthcare Solutions, INC. | $511.78 | 2020-2025 | Libtayo |
| Pfizer INC. | $394.03 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $361.07 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $337.05 | 2022-2025 | |
| Ucb, INC. | $317.55 | 2021-2025 | Bimzelx |
| Janssen Biotech, INC. | $288.44 | 2020-2023 | Tremfya |
| Galderma Laboratories, L.P. | $269.95 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $238.02 | 2019-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.35 | 2023-2024 | Spevigo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $179.20 | 2023-2025 | Zoryve |
| Mallinckrodt Hospital Products INC. | $135.36 | 2025 | Acthar |
| Dermira, INC. | $128.59 | 2019 | |
| Verrica Pharmaceuticals INC. | $128.56 | 2023 | Ycanth |
| Vyne Pharmaceuticals INC. | $124.50 | 2020 | |
| Kyowa Kirin, INC. | $118.74 | 2023 | Poteligeo |
| Almirall LLC | $117.77 | 2022 | |
| Abbvie INC. | $116.39 | 2019 | |
| Janssen Scientific Affairs, LLC | $113.26 | 2020 | |
| Sun Pharmaceutical Industries INC. | $105.63 | 2022 | |
| Sandoz INC. | $34.92 | 2020 | |
| Botanix Sb INC | $19.01 | 2025 | Sofdra |
| Organon LLC | $17.14 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $16.01 | 2023 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Sebela Pharmaceuticals INC. | $15.00 | 2020 | |
| Merck Sharp & Dohme LLC | $14.22 | 2019 | |
| Mission Pharmacal Company | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.